200 related articles for article (PubMed ID: 12771996)
21. Clinical relevance of immunoactive mistletoe lectin-I.
Beuth J
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
[TBL] [Abstract][Full Text] [Related]
22. Isolation and characterization of biologically active lectin from Korean mistletoe, Viscum album var. Coloratum.
Lee HS; Kim YS; Kim SB; Choi BE; Woo BH; Lee KC
Cell Mol Life Sci; 1999 Apr; 55(4):679-82. PubMed ID: 10357236
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins.
Ribéreau-Gayon G; Jung ML; Frantz M; Anton R
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S3-8. PubMed ID: 9179359
[TBL] [Abstract][Full Text] [Related]
24. Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.
Mengs U; Göthel D; Leng-Peschlow E
Anticancer Res; 2002; 22(3):1399-407. PubMed ID: 12168816
[TBL] [Abstract][Full Text] [Related]
25. Induction of apoptosis by mistletoe lectin I and its subunits. No evidence for cytotoxic effects caused by isolated A- and B-chains.
Vervecken W; Kleff S; Pfüller U; Büssing A
Int J Biochem Cell Biol; 2000 Mar; 32(3):317-26. PubMed ID: 10716629
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms involved in spontaneous and Viscum album agglutinin-I-induced human neutrophil apoptosis: Viscum album agglutinin-I accelerates the loss of antiapoptotic Mcl-1 expression and the degradation of cytoskeletal paxillin and vimentin proteins via caspases.
Lavastre V; Pelletier M; Saller R; Hostanska K; Girard D
J Immunol; 2002 Feb; 168(3):1419-27. PubMed ID: 11801684
[TBL] [Abstract][Full Text] [Related]
27. Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma.
Pryme IF; Bardocz S; Pusztai A; Ewen SW
Histol Histopathol; 2002 Jan; 17(1):261-71. PubMed ID: 11820217
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins.
Büssing A; Schietzel M
Anticancer Res; 1999; 19(1A):23-8. PubMed ID: 10226520
[TBL] [Abstract][Full Text] [Related]
29. Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins.
Pryme IF; Bardocz S; Pusztai A; Ewen SW
Histol Histopathol; 2006 Mar; 21(3):285-99. PubMed ID: 16372250
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of the recombinant A-chain of a type II ribosome-inactivating protein (RIP) from Viscum album coloratum and structural basis on its ribosome-inactivating activity and the sugar-binding properties of the B-chain.
Ye W; Nanga RP; Kang CB; Song JH; Song SK; Yoon HS
J Biochem Mol Biol; 2006 Sep; 39(5):560-70. PubMed ID: 17002877
[TBL] [Abstract][Full Text] [Related]
31. Mistletoe lectins: telomerase inhibitors in alternative cancer therapy.
Li SS
Drug Discov Today; 2002 Sep; 7(17):896-7. PubMed ID: 12546929
[No Abstract] [Full Text] [Related]
32. Roles of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in apoptosis of human monoblastic leukemia U937 cells by lectin-II isolated from Korean mistletoe.
Pae HO; Oh GS; Kim NY; Shin MK; Lee HS; Yun YG; Oh H; Kim YM; Chung HT
In Vitr Mol Toxicol; 2001; 14(2):99-106. PubMed ID: 11690563
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro.
Kelter G; Schierholz JM; Fischer IU; Fiebig HH
Anticancer Res; 2007; 27(1A):223-33. PubMed ID: 17352237
[TBL] [Abstract][Full Text] [Related]
34. [Mistletoe therapy from the pharmacologic perspective].
Hajto T; Hostanska K; Saller R
Forsch Komplementarmed; 1999 Aug; 6(4):186-94. PubMed ID: 10529578
[TBL] [Abstract][Full Text] [Related]
35. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations.
Zuzak TJ; Rist L; Eggenschwiler J; Grotzer MA; Viviani A
Anticancer Res; 2006; 26(5A):3485-92. PubMed ID: 17094471
[TBL] [Abstract][Full Text] [Related]
36. Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain.
Eck J; Langer M; Möckel B; Baur A; Rothe M; Zinke H; Lentzen H
Eur J Biochem; 1999 Sep; 264(3):775-84. PubMed ID: 10491123
[TBL] [Abstract][Full Text] [Related]
37. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro.
Stettin A; Schultze JL; Stechemesser E; Berg PA
Klin Wochenschr; 1990 Sep; 68(18):896-900. PubMed ID: 2124308
[TBL] [Abstract][Full Text] [Related]
38. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts.
Gabius HJ; Darro F; Remmelink M; André S; Kopitz J; Danguy A; Gabius S; Salmon I; Kiss R
Cancer Invest; 2001; 19(2):114-26. PubMed ID: 11296616
[TBL] [Abstract][Full Text] [Related]
39. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response.
Kunze E; Schulz H; Adamek M; Gabius HJ
J Cancer Res Clin Oncol; 2000 Mar; 126(3):125-38. PubMed ID: 10741906
[TBL] [Abstract][Full Text] [Related]
40. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1.
Beuth J; Ko HL; Tunggal L; Steuer MK; Geisel J; Jeljaszewicz J; Pulverer G
In Vivo; 1993; 7(5):407-10. PubMed ID: 8110981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
